ClinicalTrials.gg
Not yet recruitingNCT06942156OPTIMIZE-HTxUpdated Apr 24, 2025

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

A Phase 4 interventional study of Everolimus and Mycophenolate mofetil Tablet/Capsule in Heart Transplant, sponsored by Chong Kun Dang Pharmaceutical. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.

Read the detailed description

This study is a prospective, multicenter, open-label, randomized, comparative, phase 4 trial to optimize immunosuppressive therapy using everolimus and low-dose calcineurin inhibitors in heart transplant patients in Korea.

02

Conditions studied

  • Heart Transplant

Keywords

  • Heart transplant
  • Everolimus
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Over 19 years old
  2. Patients with stable heart transplant graft function at least 28\~100 days post transplant.
  3. Patients who are appropriate for combination therapy with Everolimus and Calcineurin inhibitor (CNI) at the investigator's discretion

Exclusion criteria

Exclusion Criteria:

  1. Recipients who have had a prior organ transplant, or who underwent a heart transplant with the simultaneous transplantation of another organ.
  2. Recipients of heart from ABO-incompatible donor
  3. Recipients of heart from the donor aged 70 or older
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Certirobell Tablet

    Everolimus

    Drug: Everolimus

  • Active comparator
    Myrept Tablet/Capsule

    Mycophenolate mofetil

    Drug: Mycophenolate mofetil Tablet/Capsule

Interventions

  • Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit

    Also known as: Certirobell Tablet

  • DrugMycophenolate mofetil Tablet/Capsule

    Drug page: Mycophenolic Acid

    Up to 1.5g BID(total 3g daily), PO

    Also known as: Myrept® Cap./Tab.

06

What researchers measure

Primary outcomes

  1. hierarchical composite assessed using the win-ratio

    hierarchical composite assessed using the win-ratio, including graft survival, treated rejection episodes, change in percent atheroma volume, and change in eGFR.

    Time frame: baseline, 12 months

Secondary outcomes

  1. Graft rejection

    Time to onset of Graft rejection

    Time frame: Baseline and 6, 12 months after drug administrations

  2. Newly developed Graft dysfunction

    Frequency of incidence

    Time frame: Baseline and 6, 12 months after drug administrations

  3. Change in renal function

    Change in eGFR

    Time frame: Baseline and 6, 12 months after drug administrations

  4. CAV ISHLT grade

    Coronary Arterial Vasculopathy(CAV) assessed by ISHLT grade for CAV (ISHLT: International Society for Heart and Lung Transplantation) * CAV0 (Not significant): No detectable angiographic lesion * CAV1 (Mild): Angiographic LM\<50% or Primary vessel with maximum lesion\<70% or Branch stenosis\<70% * CAV2 (Moderate): Angiographic LM\<50%, Single primary vessel≥70% or Isolated branch stenosis in 2 system≥70% * CAV3 (Severe): Angiographic LM≥50% or ≥2 primary vessels ≥70% or Isolated branch stenosis in all 3 system≥70% or CAV1 or CAV2 with allograft dysfunction (LVEF≤45%) or evidence of significant restrictive physiology

    Time frame: Until 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Dec 2030, 64 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 24, 2025
StartEst.
Aug 14, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942156
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Aug 14, 2025 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 24, 2025

Study contacts

Jin-O Choi, MD, PhD
Contact
choijean5@gmail.com
02-3410-3419
Jin-O Choi, MD, PhD
study chair · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion